Group 1 - The company expects a net profit attributable to shareholders for the first half of 2025 to be between 127.43 million and 141.08 million yuan, representing a growth of 40% to 55% compared to 91.02 million yuan in the same period last year [2] - The growth in performance is attributed to the strong sales of veterinary chemical products, particularly the sales of the main product, chlortetracycline, in both domestic and overseas markets, with significant growth in overseas sales [2] - The company's production capacity has increased following the launch of its sixth-phase project, which has ensured supply to both domestic and international markets, contributing to higher profits [2] Group 2 - The global beef cattle industry is entering a new cyclical turning point, with average prices for ground beef in the U.S. rising nearly 12% year-on-year in June, and unprocessed beef steak prices increasing by 8%, reaching historical highs [2] - The rising prices of beef and live cattle in the U.S. are expected to boost the demand for veterinary drugs for live cattle, as local ranchers become less sensitive to drug prices due to increased profits from higher beef prices [2] - The company is the largest producer of veterinary chlortetracycline globally, with 60% to 70% of its products sold overseas, primarily in the U.S., which accounts for about two-thirds of its exports [3] Group 3 - As of July 11, 2025, the wholesale price of beef in China was 63.56 yuan per kilogram, an increase of 4.51% year-on-year, while the price of calves rose to 29.81 yuan per kilogram, up 26.37% year-on-year [4] - The decline in cattle inventory and the rising price of calves are expected to support beef prices in the second half of 2025 and into 2026, indicating a continuation of the beef cycle's prosperity [4] - The company is enhancing its leading position in the chlortetracycline market due to increased usage in large-scale farming and the development of a new animal brucellosis vaccine that has won a major procurement project [4]
金河生物:上半年净利润预计增长40%—55% 海内外肉牛养殖景气度回暖 产品有望量价齐升